Mukesh Sehdev

Mukesh Sehdev is an experienced professional in the field of Chemistry, Manufacturing, and Controls (CMC) with a robust background spanning over three decades. Currently serving as the Head of CMC at Akari Therapeutics, PLC since March 2019, Mukesh is responsible for developing CMC strategies for various products and managing global regulatory and vendor operations. Concurrently, Mukesh works as an Independent CMC Consultant at Sehdev Biopharma Ltd. Previously, Mukesh has held key roles such as Global Project Leader CMC at Sanofi Belgium, where successful approvals for Caplacizumab were achieved, and Head of CMC at both Prothena and Oxurion NV, contributing to multiple product advancements and regulatory submissions. Mukesh began a career at UCB, focusing on bio-process development and optimisation. Educational qualifications include an MSc in Pharmaceutical Medicine from the University of Surrey and a BSc in Science from the University of East London.